Overview
Current Hematologic Malignancy Reports, published by Springer Science+Business Media (United States), published 167 papers in 2021–2025, and its papers received 1,943 citations in those years. Its h-index is 58 and its two-year mean citedness is 3.75. On the ITS Journal Score it ranks #7,510 of 62,158 ranked journals and #1,771 of 8,757 in Medicine.
Key figures
Citations count every citation the journal's papers received in these years, including citations to older papers. Two-year mean citedness is OpenAlex's measure of how often recent papers are cited; it is similar in idea to, but not the same as, an impact factor.
Papers and citations by year
| Year | Papers | Citations received | Open-access papers |
|---|---|---|---|
| 2020 | 46 | 1,062 | 12 |
| 2021 | 55 | 827 | 15 |
| 2022 | 29 | 381 | 9 |
| 2023 | 35 | 489 | 13 |
| 2024 | 26 | 192 | 11 |
| 2025 | 22 | 54 | 11 |
What it publishes
The leading research topics of its papers (OpenAlex topic classification). Select a topic to find other journals that publish on it.
Similar journals
Ranked journals that publish on the same topics.
| Journal | Field | Score | Papers 2021–2025 | Open access |
|---|---|---|---|---|
| Leukemia | Medicine | 86.7 | 1,729 | 76% |
| Leukemia Research | Medicine | 68.6 | 1,416 | 17% |
| Leukemia & lymphoma/Leukemia and lymphoma | Medicine | 72.3 | 1,847 | 27% |
| Haematologica | Medicine | 76.1 | 2,199 | 100% |
| Leukemia Research Reports | Medicine | 49.5 | 315 | 100% |
| Blood and Lymphatic Cancer Targets and Therapy | Medicine | 46.4 | 50 | 100% |
| Best Practice & Research Clinical Haematology | Medicine | 73.8 | 235 | 32% |
| Hematological Oncology | Medicine | 63.8 | 2,703 | 86% |
Identity and sources
- ISSN-L: 1558-8211
- Print ISSN: 1558-8211
- Electronic ISSN: 1558-822X
- Publisher: Springer Science+Business Media
- Listed in DOAJ: Not yet checked
- Crossref: Not yet checked
- OpenAlex: S35022943
- Journal website: www.springer.com
Figures come from OpenAlex (papers, citations, h-index, topics), Crossref (ISSN check) and DOAJ (open-access listing and fees). They change as records are corrected, so treat them as a dated snapshot. This page does not state whether the journal is indexed in Scopus, Web of Science or PubMed.
Questions
What is the ITS Journal Score of Current Hematologic Malignancy Reports?
It is 68.8 out of 100, which places it #7,510 among ranked journals. The score combines citation impact (45%), h-index (35%) and size (20%) from open OpenAlex data.
What is the impact factor of Current Hematologic Malignancy Reports?
This site does not publish Journal Impact Factors, which belong to Clarivate. As an open alternative, its two-year mean citedness in OpenAlex is 3.75.
Is Current Hematologic Malignancy Reports open access?
35% of its papers from 2021–2025 are recorded as open access.
Does Current Hematologic Malignancy Reports charge a publication fee?
No fee is recorded in the open data used here. Check the journal's own website for its current fees.